Abstract: For 30 years, medical professionals have sought the "magic buIlet" which would allow sensitive detection of disease and facilitate localized administration of potent chemotherapeutic agents without systemic toxicities. Ligand targeted ultrasonic contrast agents have the potential to improve diagnostic sensitivity, port drugs to specific pathologic tissues, and provide dosimetry of the delivered therapeutics. A ligand directed, lipid encapsulated perfluorocarbon emulsion particle (250 nm diameter) contrast system has been recently developed and demonstrated both in vitro and in viva to strikingly increase the acoustic reflectivity when bound. The magnitude of enhancement has been tentatively explained by an acoustic transmission line model. The contrast agent has a one hour circulatory half-life which facilitates successful systemic targeting. The small particle size of these emulsions affords access to tiny capillary beds and vascular endothelial disruptions such as those post-angioplasty. These studies suggest perfluorocarbon contrast agents can target molecular epitopes within and proximate to the systemic circulation which will create opportunities for ultrasound in medical diagnosis and therapy.
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Often ultrasonic contrast differences between healthy and pathological tissues are subtle. The recent development of ultrasonic blood pool agents, primarily microbubble formulations, have improved delineation of cardiac anatomical perfusional patterns. However, these agent provide no specific improvement in the differential signal intensity between abnormal and background tissues except as revealed by altered blood flow patterns. We have recently developed a novel, targeted contrast system 1 based upon emulsion technology. The particle is a 250 nm, lipid encapsulated, perfluorocarbon emulsion which takes advantage of avidin-biotin interactions to couple pretargeted ligands (monoclonal antibodies) to the contrast particle. The targeted contrast agent is produced by incorporating biotinylated phosphatidylethanolamine into the outer lipid monolayer of the emulsion. A control emulsions exclude the biotinylated phosphatidylethanolamine from the outer surfactant layer. The ligand-directed system utilizes three steps: 1) a biotinylated ligand (monoclonal antibody) is administered and binds the target tissue; 2) avidin, an egg white protein, is given which binds to and cross-links the biotinylated ligand on the targeted tissue surface; 3). the biotinylated perfluorocarbon emulsion is -0. administered and binds to the avidin through unoccupied biotin PFDCO =Cl.lS~z~-~~~ ~30.21e~.~'~ binding sites. The apposition and concentration of contrast particles over the surface of the tissue increases the ultrasonic reflectivity of the tissue in routine 2D echocardiographic images. As opposed to blood perfusion agents, the circulating contrast particles have low inherent echogenicity which improves the overall signaI-to-noise ratios of the contrast effects 0 60 zlf3 (It%) 240 300
To date, several investigators have utilized biotinylated Figure 2 . Pharmacokinetics of contrast agent antibodies and labeled avidins or biotins to target pathologic tissues with poor signal to noise ratios regardless of the imaging modality*. Attempts to enhance these applications with the use of particles, typically liposomes, have worked well in vitro but generally failed in vivo due to a short half-life or impaired target binding 3. Accordingly, we characterized the pharmacokinetic distribution and elimination profiles of the targeted contrast system in three canines following intravenous bolus injection of our new contrast system. In each animal, intravenous access was established in the brachial vein and emulsion (10 cc) was administered by bolus. Venous blood samples were drawn and analyzed in duplicate for perfluorocarbon concentration by gas-liquid chromatography using flame-ionization detection. A biexponential model C = A&-at + Bee-fit was fit to the data and a a-elimination half-life (ttn ) of 64 + 3 minutes was determined (Figure 2) .
We further demonstrated the efficacy of the contrast
Carotid Artery Thrombus
agent to be administered intravenously, circulate and enhance
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electrically induced arterial thrombi, preexposed in situ to anti-fibrin antibody 4 and avidin, in the carotid arterial segments of 9 mongrel dogs. As noted in Figure 3 , the targeted pet-fluorocarbon emulsion was able to circulate, localize and clearly enhance the acoustic reflectivity of the clots using a commercially available echocardiography system Anode Thrombus with a 7.5 MHz linear phased array transducer. Figure 3 . Increased acoustic reflectivity of dog Acoustic microscopy studies were employed to arterial thrombus following targeted contrast agent. quantify the increase in ultrasonic reflectivity when the contrast system bound to substrates of varying inherent echogenicity. The targeted contrast system was bound to nitrocellulose membranes, whole blood clots and fibrin plasma clots which increased the average acoustic reflectivity by 7% 1.1, 8.6 k 0.9 and 36.0 f 2.6 dB, respectively. Moreover, using reasonable assumptions, first-order approximations of reflectivity enhancement predicted using a simple linear acoustics transmission line model, 5, 8 and 29 dB, respectively.
The targeted contrast agent also can delineate the induction of protein expression associated with pathologic processes by penetrating through microscopic disruptions of porcine carotid endothelial linings to specifically localize "tissue factor" elaborated within the wall of balloon-injured arteries. Accordingly, tissue factor represents the proximate source of arterial clot formation in atherosclerosis, leading to artery occlusion, and has been associated with restenosis after angioplasty 5. Both carotid arteries of three pigs (20kg) were injured using an 8 x 20 mm angioplasty balloon. The carotids were treated in situ with either targeted contrast agent employing a polyclonal antibody to tissue factor or control contrast agent. Intravascular ultrasound (20 MHz)was used to image the arteries before and after exposure to the emulsions and revealed acoustic enhancement of the subintima and tunica media at the site of balloon-induced injury compared with control contrast arteries. (~~0.05) (Figure 4. ). Immunohistochemical staining confirmed the c Figure 4 . Enhancement of carotid tissue presence of increased tissue factor at the sites of acoustic enhancement. factor post-angioplasty.
These studies suggest perfluorocarbon contrast agents can target molecular epitopes within and proximate to the systemic circulation. These agents are creating new and exciting opportunities for ultrasound in medical diagnosis and therapy.
